2024    2023    2022    2021    2020    2019    2018    2017    2016   

2016

Articles

1 - 

Natural history of perianal Crohn's disease: long-term follow-up on a population-based cohort

M. -L. Rabilloud, A. -L. Mallet, L. Siproudhis, Emma Bajeux, Jean François Viel, I. Tron, J. -F. Bretagne, M. Robaszkiewicz, G. Bouguen

Journal of Crohn's and Colitis, 2016, 10 (suppl 1), pp.S175--S176.

DOI : https://doi.org/10.1093/ecco-jcc/jjw019.290

 

2 - 

Management of urinary stone disease in general practice: A French Delphi study

Sandra Abergel, Benoit Peyronnet, Philippe Seguin, Karim Bensalah, Olivier Traxer, Yonathan Freund

European Journal of General Practice, 2016, 22 (2), pp.103--110.

DOI : https://doi.org/10.3109/13814788.2016.1149568

Pubmed : 27092401

 

3 - 

A negative screening does not eliminate tuberculosis risk under anti-TNF treatment in inflammatory bowel disease: a descriptive study

Y. Abitbol, D. Laharie, J. Cosnes, M. Allez, S. Nancey, Audrey Amiot, A. Aubourg, Mathurin Fumery, R. Altwegg, P. Michetti et al.

Journal of Crohn's and Colitis, 2016, 10 (4), pp.S382--S382.

DOI : https://doi.org/10.1016/S0016-5085(16)31437-8

 

4 - 

Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort

Yael Abitbol, David Laharie, Jacques Cosnes, Matthieu Allez, Stephane Nancey, Aurelien Amiot, Alexandre Aubourg, Mathurin Fumery, Romain Altwegg, Pierre Michetti et al.

Journal of Crohn's and Colitis, 2016, 10 (10), pp.1179-1185.

DOI : https://doi.org/10.1093/ecco-jcc/jjw129

Pubmed : 27402916

 

5 - 

The rs3957357C>T SNP in GSTA1 Is Associated with a Higher Risk of Occurrence of Hepatocellular Carcinoma in European Individuals

Hanane Akhdar, Said El Shamieh, Orlando Musso, Romain Désert, Wissam Joumaa, Dominique Guyader, Caroline Aninat, Anne Corlu, Fabrice Morel

PLoS ONE, 2016, 11 (12), pp.e0167543.

DOI : https://doi.org/10.1371/journal.pone.0167543

Pubmed : 27936036

 

6 - 

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients with Inflammatory Bowel Disease

Aurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, Jérome Filippi, Benjamin Pariente, Xavier Roblin, Anthony Buisson, Carmen Stefanescu, Caroline Trang-Poisson, Romain Altwegg et al.

Clinical Gastroenterology and Hepatology, 2016, 14 (11), pp.1593-1601.e2.

DOI : https://doi.org/10.1016/j.cgh.2016.02.016

Pubmed : 26917043

 

7 - 

Safety of recombinant factor VIIa in patients under extracorporeal membrane oxygenation

Amedeo Anselmi, Patrick Guinet, Vito Giovanni Ruggieri, Marie Aymami, Bernard Lelong, Solène Granry, Yannick Mallédant, Yves Le Tulzo, Pierre Gueret, Jean-Philippe Verhoye et al.

European Journal of Cardio-Thoracic Surgery, 2016, 49 (1), pp.78-84.

DOI : https://doi.org/10.1093/ejcts/ezv140

Pubmed : 25908783

 

8 - 

Poly(trimethylene carbonate)/Poly(malic acid) Amphiphilic Diblock Copolymers as Biocompatible Nanoparticles

Ghislaine Barouti, Ali Khalil, Clement Orione, Kathleen Jarnouen, Sandrine Cammas-Marion, Pascal Loyer, Sophie M Guillaume

Chemistry - A European Journal, 2016, 22 (8), pp.2819-2830.

DOI : https://doi.org/10.1002/chem.201504824

Pubmed : 26791328

 

9 - 

LOXL2 is a prognosis biomarker and a potential therapeutic target in intrahepatic cholangiocarcinoma

D. Bergeat, A. Fautrel, Bruno Turlin, A. Merdrignac, M. Rayar, B. Meunier, B. Clement, K. Boudjema, C. Coulouarn, L Sulpice et al.

HPB, 2016, Abstracts of the 11th International Congress of the European-African Hepato-Pancreato-Biliary Association, 21-24 April 2015, Manchester, UK, 18, Supplement 2, pp.e863.

DOI : https://doi.org/10.1016/j.hpb.2016.01.490

 

10 - 

Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma

Damien Bergeat, Alain Fautrel, Bruno Turlin, Aude Merdrignac, Michel Rayar, Karim Boudjema, Cédric Coulouarn, Laurent Sulpice

Journal of Surgical Research, 2016, 203 (2), pp.441-50.

DOI : https://doi.org/10.1016/j.jss.2016.03.044

Pubmed : 27363654